Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.
about
Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsMeasuring the symptom burden associated with the treatment of chronic myeloid leukemiaHow could patient reported outcomes improve patient management in chronic myeloid leukemia?Measuring symptoms as a critical component of drug development and evaluation in hematological diseasesEffectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision AnalysisGas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents.Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.Treatments for chronic myeloid leukemia: a qualitative systematic review.Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia.Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia.A new health-related quality of life instrument for leukemia: will it be widely adopted soon?Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.Bosutinib in chronic myeloid leukemia: patient selection and perspectives.
P2860
Q27004032-C7013829-9499-4FC0-849D-4D0BE0247ED3Q28689231-C5FA1261-DC17-40A0-ACAC-2B03F73E26F5Q30241092-46DABE51-BAB0-490F-BDF3-34D21BA0F612Q33705743-787E9ABD-76B6-4AB9-8105-F235041E5DE3Q36400944-C0093DA9-38CF-4E5E-9883-7A7C1EEBC4E2Q36808017-67462417-2D94-42F5-9D76-17BA52A8EAA2Q37579983-D62C1A21-2F11-4283-B70A-23849578E933Q37682689-8AB1245A-10E8-4740-B903-B89B2DF9A4B0Q38037079-88559788-674F-4AF9-B99C-A8EAE7E597DFQ38093654-F3C53BA3-51E3-4E99-B79D-EAF1386FCEF2Q38135813-D7DCF658-8E60-4DD2-B710-1BE8656131E4Q38178192-C0CBFEC8-451C-4F3F-AA6B-2E7E95E4D514Q38934423-79B8EA3E-CC6B-460B-A082-A5C24B9DD032Q39797514-590B71E4-4B21-4C38-A175-F4CF7561E498Q41203712-8D38C0E6-9353-47A3-9A49-7BCEF4C982DCQ41858582-4FFF2C08-4194-4685-9201-317D97E2DFA4Q47551814-B78C73E8-A80D-48C6-9CDA-138EB65DE5D2Q48124245-EE0F5336-5FAB-4D20-8783-C0C2FF825AADQ50586934-E1656F29-C76C-40A0-9CCF-050DBFDFF3EDQ52562694-8D1E1268-016A-40EB-BA23-536EBAF0C826
P2860
Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Health-related quality of life ...... hase chronic myeloid leukemia.
@en
Health-related quality of life of bosutinib
@nl
type
label
Health-related quality of life ...... hase chronic myeloid leukemia.
@en
Health-related quality of life of bosutinib
@nl
prefLabel
Health-related quality of life ...... hase chronic myeloid leukemia.
@en
Health-related quality of life of bosutinib
@nl
P2093
P921
P1433
P1476
Health-related quality of life ...... hase chronic myeloid leukemia.
@en
P2093
Dong-Wook Kim
Nadine Besson
Peter C Trask
Virginia Kelly
P304
P356
10.1016/J.LEUKRES.2011.10.011
P577
2011-10-28T00:00:00Z